Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells

Gene Therapy

Volumn 7, Issue 16, 2000, Pages 1410-1416

  Geutskens, S B ^a   Van Der Eb, M M ^a   Plomp, A C ^b   Jonges, L E ^a   Cramer, S J ^a   Ensink, N G ^a   Kuppen, P J K ^a   Hoeben, R C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Adjuvant; Cancer gene therapy; IL 2; Recombinant adenovirus

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DNA TRANSFER; GENE EXPRESSION; GENE THERAPY; IMMUNE RESPONSE; IMMUNOTHERAPY; LIVER METASTASIS; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; T LYMPHOCYTE; TRANSGENE; TUMOR CELL; TUMOR REGRESSION; VIRUS PLAQUE; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES;

EID: 0033843263     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301251     Document Type: Article

References (41)

1. Interleukin-2 gene therapy of surgical minimal residual tumor disease
2. Cytokine gene therapy or infusion as treatment for solid human cancer
3. Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells
4. Intratumoral injection of an adenovirus expressing interleukin-2 induces regression and immunity in a murine breast cancer model
5. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma-interferon
6. Effective genetic therapy of established medullary thyroid carcinomas with murine interleukin-2: Dissemination and cytotoxicity studies in a rat tumor model
7. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts
8. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response
9. Natural history and therapy of metastatic renal cell carcinoma, the role of interleukin-2
10. Toxicity of human recombinant interleukin-2 in rats. Pathologic changes are characterized by marked lymphocytic and eosinophilic proliferation and multisystem involvement
11. Interleukin-2 toxicity
12. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2
13. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer
14. Combination gene therapy for liver metastasis of colon carcinoma in vivo
15. Long-term survival of immunocompetent rats with intraperitoneal colon carcinoma tumors using herpes simplex thymidine kinase/ganciclovir and IL-2 treatments
16. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model
17. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors
18. Interleukin-2 in cancer therapy
19. Immunotherapy and immunity to cancer: Cellular mechanisms
20. Cellular immunity delimits adenoviral gene therapy strategies for the treatment of neoplastic diseases
21. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo
22. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration
23. Regional administration of natural killer cells in a rat hepatic metastasis model results in better tumor infiltration and anti-tumor response than systemic administration
24. Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes
25. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line
26. Lipofection indirectly increases expression of endogenous major histocompatibility complex class I molecules on tumor cells
27. Adenoviruses activate human dendritic cells without polarization towards a T helper type 1-inducing subset
28. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake
29. Analysis of the specificity and mechanism of transcriptional activation of the human hsp70 gene during infection by DNA viruses
30. Heat shock protein expression in target cells infected with low levels of replication-competent virus contributes to the immunogenicity of adenoviral vectors
31. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses
32. Diabetes induced by Coxsackie virus: Initiation by bystander damage and not molecular mimicry
33. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression
34. Liver metastasis model of colon cancer in the rat: Immunohistochemical characterization
35. Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors
36. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice
37. Specific tumor-cell killing with adenovirus vectors containing the apoptin gene
38. A rapid biologic assay for the detection of interleukin 1
39. The purification and characterization of rat gamma interferon by use of two monoclonal antibodies
40. Interstitial class II-positive cell depletion by donor pretreatment with gamma irradiation. Evidence of differential immunogenicity between vascularized cardiac allografts and islets
41. Identification of monoclonal antibodies reactive with the rat homolog of ICAM-1, and evidence for a differential involvement of ICAM-1 in the adherence of resting versus activated lymphocytes to high endothelial cells